The latest price target for Stoke Therapeutics (NASDAQ:STOK) was reported by Chardan Capital on February 19, 2025. The analyst firm set a price target for $24.00 expecting STOK to rise to within 12 months (a possible 185.71% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Stoke Therapeutics (NASDAQ:STOK) was provided by Chardan Capital, and Stoke Therapeutics maintained their buy rating.

The last upgrade for Stoke Therapeutics Inc happened on March 26, 2024 when TD Cowen raised their price target to N/A. TD Cowen previously had a hold for Stoke Therapeutics Inc.

There is no last downgrade for Stoke Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Stoke Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Stoke Therapeutics was filed on February 19, 2025 so you should expect the next rating to be made available sometime around February 19, 2026.

While ratings are subjective and will change, the latest Stoke Therapeutics (STOK) rating was a maintained with a price target of $24.00 to $24.00. The current price Stoke Therapeutics (STOK) is trading at is $8.40, which is out of the analyst’s predicted range.